Edward Tenthoff
Stock Analyst at Piper Sandler
(3.28)
# 1,121
Out of 4,412 analysts
132
Total ratings
39.39%
Success rate
3.8%
Average return
Main Sectors:
Top Industries:
46 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPSC Century Therapeutics | Reiterates: Overweight | $10 → $9 | $2.88 | +212.50% | 5 | Apr 12, 2024 | |
| SYRS Syros Pharmaceuticals | Reiterates: Overweight | $13 | $5.04 | +157.94% | 4 | Apr 3, 2024 | |
| CUE Cue Biopharma | Reiterates: Overweight | $8 | $1.37 | +486.08% | 3 | Apr 3, 2024 | |
| APTO Aptose Biosciences | Maintains: Overweight | $5 | $1.22 | +309.84% | 4 | Apr 3, 2024 | |
| STRO Sutro Biopharma | Reiterates: Overweight | $12 → $11 | $3.42 | +221.64% | 5 | Apr 3, 2024 | |
| OMGA Omega Therapeutics | Reiterates: Overweight | $10 → $9 | $2.27 | +296.48% | 4 | Apr 3, 2024 | |
| OPK OPKO Health | Reiterates: Overweight | $5 | $1.26 | +296.83% | 3 | Apr 1, 2024 | |
| SKYE Skye Bioscience | Reiterates: Overweight | $12 → $20 | $13.00 | +53.85% | 2 | Mar 14, 2024 | |
| ASLN ASLAN Pharmaceuticals | Reiterates: Overweight | $15 → $10 | $0.42 | +2,307.90% | 5 | Mar 13, 2024 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $27 → $29 | $24.73 | +17.27% | 2 | Mar 6, 2024 | |
| MIST Milestone Pharmaceuticals | Maintains: Overweight | $6 → $5 | $1.56 | +220.51% | 3 | Mar 5, 2024 | |
| XNCR Xencor | Downgrades: Neutral | $37 → $24 | $19.98 | +20.12% | 2 | Feb 28, 2024 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $13 → $15 | $7.12 | +110.67% | 3 | Feb 28, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $39 → $56 | $33.37 | +67.82% | 4 | Feb 27, 2024 | |
| KRON Kronos Bio | Maintains: Overweight | $7 → $6 | $1.00 | +500.00% | 4 | Dec 19, 2023 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $210 → $217 | $143.31 | +51.42% | 4 | Dec 14, 2023 | |
| PSTX Poseida Therapeutics | Maintains: Overweight | $8 → $10 | $2.13 | +369.48% | 3 | Dec 11, 2023 | |
| ARVN Arvinas | Maintains: Overweight | $70 → $55 | $32.37 | +69.91% | 5 | Oct 23, 2023 | |
| GRTS Gritstone bio | Maintains: Overweight | $6 → $7 | $0.81 | +760.59% | 2 | Sep 28, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $28 → $31 | $8.10 | +282.72% | 5 | Aug 14, 2023 | |
| GRTX Galera Therapeutics | Downgrades: Neutral | $6 → $0.5 | $0.19 | +168.67% | 2 | Aug 10, 2023 | |
| MESO Mesoblast | Downgrades: Neutral | $28 → $8 | $6.24 | +28.21% | 2 | Aug 4, 2023 | |
| LIFE aTyr Pharma | Maintains: Overweight | $13 → $20 | $1.57 | +1,173.89% | 5 | Jul 21, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | $52 → $59 | $22.12 | +166.73% | 6 | Jun 2, 2023 | |
| TPST Tempest Therapeutics | Maintains: Overweight | $10 → $6 | $3.54 | +69.49% | 2 | Mar 23, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | $71 → $12 | $3.80 | +215.79% | 3 | Jan 6, 2023 | |
| MRNA Moderna | Maintains: Overweight | $214 → $217 | $107.97 | +100.98% | 7 | Dec 20, 2022 | |
| LEGN Legend Biotech | Maintains: Overweight | $72 → $78 | $45.30 | +72.19% | 2 | Dec 20, 2022 | |
| XFOR X4 Pharmaceuticals | Initiates: Overweight | $3 | $1.17 | +157.51% | 1 | Dec 12, 2022 | |
| NXTC NextCure | Maintains: Overweight | $13 → $6 | $1.35 | +344.44% | 2 | Nov 4, 2022 | |
| MCRB Seres Therapeutics | Maintains: Overweight | $7 → $9 | $0.83 | +990.91% | 3 | Sep 7, 2022 | |
| PRTC PureTech Health | Maintains: Overweight | $37 → $44 | $28.50 | +54.39% | 1 | Aug 25, 2022 | |
| CRSP CRISPR Therapeutics AG | Maintains: Overweight | $115 → $121 | $53.91 | +124.45% | 3 | Jun 22, 2022 | |
| ELOX Eloxx Pharmaceuticals | Maintains: Overweight | $160 → $60 | $0.81 | +7,346.11% | 1 | May 23, 2022 | |
| BCYC Bicycle Therapeutics | Maintains: Overweight | $76 → $37 | $22.71 | +62.92% | 1 | May 23, 2022 | |
| APVO Aptevo Therapeutics | Maintains: Overweight | $3,036 → $880 | $0.71 | +124,528.24% | 3 | May 13, 2022 | |
| GLUE Monte Rosa Therapeutics | Maintains: Overweight | $40 → $21 | $5.33 | +294.00% | 2 | May 12, 2022 | |
| ARGX argenx SE | Upgrades: Overweight | n/a | $372.80 | - | 3 | Nov 29, 2021 | |
| SYBX Synlogic | Maintains: Overweight | n/a | $1.87 | - | 1 | Sep 20, 2021 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | n/a | $397.48 | - | 4 | Jul 30, 2021 | |
| EXEL Exelixis | Maintains: Overweight | n/a | $23.70 | - | 1 | Feb 16, 2021 | |
| MRKR Marker Therapeutics | Downgrades: Neutral | n/a | $4.30 | - | 1 | May 12, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Overweight | n/a | $0.18 | - | 1 | Jan 27, 2020 | |
| IGMS IGM Biosciences | Maintains: Overweight | n/a | $9.40 | - | 1 | Jan 6, 2020 | |
| ASNS Actelis Networks | Initiates: Overweight | n/a | $0.77 | - | 1 | Dec 11, 2017 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Overweight | n/a | $883.20 | - | 1 | Feb 13, 2017 |
Century Therapeutics
Apr 12, 2024
Reiterates: Overweight
Price Target: $10 → $9
Current: $2.88
Upside: +212.50%
Syros Pharmaceuticals
Apr 3, 2024
Reiterates: Overweight
Price Target: $13
Current: $5.04
Upside: +157.94%
Cue Biopharma
Apr 3, 2024
Reiterates: Overweight
Price Target: $8
Current: $1.37
Upside: +486.08%
Aptose Biosciences
Apr 3, 2024
Maintains: Overweight
Price Target: $5
Current: $1.22
Upside: +309.84%
Sutro Biopharma
Apr 3, 2024
Reiterates: Overweight
Price Target: $12 → $11
Current: $3.42
Upside: +221.64%
Omega Therapeutics
Apr 3, 2024
Reiterates: Overweight
Price Target: $10 → $9
Current: $2.27
Upside: +296.48%
OPKO Health
Apr 1, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.26
Upside: +296.83%
Skye Bioscience
Mar 14, 2024
Reiterates: Overweight
Price Target: $12 → $20
Current: $13.00
Upside: +53.85%
ASLAN Pharmaceuticals
Mar 13, 2024
Reiterates: Overweight
Price Target: $15 → $10
Current: $0.42
Upside: +2,307.90%
Dyne Therapeutics
Mar 6, 2024
Maintains: Overweight
Price Target: $27 → $29
Current: $24.73
Upside: +17.27%
Milestone Pharmaceuticals
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.56
Upside: +220.51%
Xencor
Feb 28, 2024
Downgrades: Neutral
Price Target: $37 → $24
Current: $19.98
Upside: +20.12%
Fulcrum Therapeutics
Feb 28, 2024
Maintains: Overweight
Price Target: $13 → $15
Current: $7.12
Upside: +110.67%
Kymera Therapeutics
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $33.37
Upside: +67.82%
Kronos Bio
Dec 19, 2023
Maintains: Overweight
Price Target: $7 → $6
Current: $1.00
Upside: +500.00%
Alnylam Pharmaceuticals
Dec 14, 2023
Maintains: Overweight
Price Target: $210 → $217
Current: $143.31
Upside: +51.42%
Poseida Therapeutics
Dec 11, 2023
Maintains: Overweight
Price Target: $8 → $10
Current: $2.13
Upside: +369.48%
Arvinas
Oct 23, 2023
Maintains: Overweight
Price Target: $70 → $55
Current: $32.37
Upside: +69.91%
Gritstone bio
Sep 28, 2023
Maintains: Overweight
Price Target: $6 → $7
Current: $0.81
Upside: +760.59%
RAPT Therapeutics
Aug 14, 2023
Maintains: Overweight
Price Target: $28 → $31
Current: $8.10
Upside: +282.72%
Galera Therapeutics
Aug 10, 2023
Downgrades: Neutral
Price Target: $6 → $0.5
Current: $0.19
Upside: +168.67%
Mesoblast
Aug 4, 2023
Downgrades: Neutral
Price Target: $28 → $8
Current: $6.24
Upside: +28.21%
aTyr Pharma
Jul 21, 2023
Maintains: Overweight
Price Target: $13 → $20
Current: $1.57
Upside: +1,173.89%
Arrowhead Pharmaceuticals
Jun 2, 2023
Maintains: Overweight
Price Target: $52 → $59
Current: $22.12
Upside: +166.73%
Tempest Therapeutics
Mar 23, 2023
Maintains: Overweight
Price Target: $10 → $6
Current: $3.54
Upside: +69.49%
Fate Therapeutics
Jan 6, 2023
Downgrades: Neutral
Price Target: $71 → $12
Current: $3.80
Upside: +215.79%
Moderna
Dec 20, 2022
Maintains: Overweight
Price Target: $214 → $217
Current: $107.97
Upside: +100.98%
Legend Biotech
Dec 20, 2022
Maintains: Overweight
Price Target: $72 → $78
Current: $45.30
Upside: +72.19%
X4 Pharmaceuticals
Dec 12, 2022
Initiates: Overweight
Price Target: $3
Current: $1.17
Upside: +157.51%
NextCure
Nov 4, 2022
Maintains: Overweight
Price Target: $13 → $6
Current: $1.35
Upside: +344.44%
Seres Therapeutics
Sep 7, 2022
Maintains: Overweight
Price Target: $7 → $9
Current: $0.83
Upside: +990.91%
PureTech Health
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $28.50
Upside: +54.39%
CRISPR Therapeutics AG
Jun 22, 2022
Maintains: Overweight
Price Target: $115 → $121
Current: $53.91
Upside: +124.45%
Eloxx Pharmaceuticals
May 23, 2022
Maintains: Overweight
Price Target: $160 → $60
Current: $0.81
Upside: +7,346.11%
Bicycle Therapeutics
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $22.71
Upside: +62.92%
Aptevo Therapeutics
May 13, 2022
Maintains: Overweight
Price Target: $3,036 → $880
Current: $0.71
Upside: +124,528.24%
Monte Rosa Therapeutics
May 12, 2022
Maintains: Overweight
Price Target: $40 → $21
Current: $5.33
Upside: +294.00%
argenx SE
Nov 29, 2021
Upgrades: Overweight
Price Target: n/a
Current: $372.80
Upside: -
Synlogic
Sep 20, 2021
Maintains: Overweight
Price Target: n/a
Current: $1.87
Upside: -
Vertex Pharmaceuticals
Jul 30, 2021
Maintains: Overweight
Price Target: n/a
Current: $397.48
Upside: -
Exelixis
Feb 16, 2021
Maintains: Overweight
Price Target: n/a
Current: $23.70
Upside: -
Marker Therapeutics
May 12, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.30
Upside: -
Matinas BioPharma Holdings
Jan 27, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.18
Upside: -
IGM Biosciences
Jan 6, 2020
Maintains: Overweight
Price Target: n/a
Current: $9.40
Upside: -
Actelis Networks
Dec 11, 2017
Initiates: Overweight
Price Target: n/a
Current: $0.77
Upside: -
Regeneron Pharmaceuticals
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $883.20
Upside: -